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ABSTRACT
Objectives: Little is known about the prevalence of
comorbidity rates in people with severe mental illness
(SMI) in UK primary care. We calculated the
prevalence of SMI by UK country, English region and
deprivation quintile, antipsychotic and antidepressant
medication prescription rates for people with
SMI, and prevalence rates of common comorbidities
in people with SMI compared with people without
SMI.
Design: Retrospective cohort study from 2000 to
2012.
Setting: 627 general practices contributing to the
Clinical Practice Research Datalink, a UK primary care
database.
Participants: Each identified case (346 551) was
matched for age, sex and general practice with 5
randomly selected control cases (1 732 755) with no
diagnosis of SMI in each yearly time point.
Outcome measures: Prevalence rates were
calculated for 16 conditions.
Results: SMI rates were highest in Scotland and in
more deprived areas. Rates increased in England,
Wales and Northern Ireland over time, with the largest
increase in Northern Ireland (0.48% in 2000/2001 to
0.69% in 2011/2012). Annual prevalence rates of all
conditions were higher in people with SMI compared
with those without SMI. The discrepancy between the
prevalence of those with and without SMI increased
over time for most conditions. A greater increase in the
mean number of additional conditions was observed in
the SMI population over the study period (0.6 in 2000/
2001 to 1.0 in 2011/2012) compared with those
without SMI (0.5 in 2000/2001 to 0.6 in 2011/2012).
For both groups, most conditions were more prevalent
in more deprived areas, whereas for the SMI group
conditions such as hypothyroidism, chronic kidney
disease and cancer were more prevalent in more
affluent areas.
Conclusions: Our findings highlight the health
inequalities faced by people with SMI. The provision of
appropriate timely health prevention, promotion and
monitoring activities to reduce these health inequalities
are needed, especially in deprived areas.
INTRODUCTION
It is well established that the physical health
of people with severe mental illness (SMI) is
much poorer than for people without SMI
and that the causes of poor physical health
in people with a SMI are complex and inter-
active.1 The factors that account for this
include adverse effects of antipsychotic medi-
cation2 and unhealthy lifestyle behaviours
which increase the likelihood of developing
obesity, hypercholesterolaemia and metabolic
syndrome, which in turn increase the risk of
chronic diseases such as diabetes mellitus.
Other barriers to recognising and managing
physical conditions include difﬁculty in
understanding healthcare advice, reduced
Strengths and limitations of this study
▪ Large UK longitudinal study to explore the preva-
lence of severe mental illness (SMI) and
comorbidity in the context of deprivation cover-
ing 12 years (2000–2012).
▪ Differences in the prevalence of SMI over time,
between countries in the UK and regions in
England are explored; increases observed
between 2000 and 2012 and highest in areas of
high deprivation.
▪ This research highlights the rising inequalities in
the pattern and number of different comorbid-
ities of this group of patients, a variable pattern
of comorbidity across the different SMI sub-
groups and areas of high and low deprivation
and has the potential to inform the provision of
appropriate and timely health prevention, promo-
tion and monitoring activities.
▪ Routinely collected clinical data were used, so
we were not able to match controls on other
important parameters such as obesity,
unemployment, ethnicity, smoking status,
alcohol or illegal drug use which may not be
recorded.
Reilly S, et al. BMJ Open 2015;5:e009010. doi:10.1136/bmjopen-2015-009010 1
Open Access Research
group.bmj.com on December 21, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
motivation to adopt new lifestyle changes, poor treat-
ment compliance, cognitive deﬁcits, reduced pain sensi-
tivity (induced by antipsychotic medication), poor
communication and social skills.3 4 Higher risk of
comorbidity is often compounded by problems of
engagement with the National Health Service (NHS)
healthcare system, for example, reluctance of general
practitioners (GPs) to participate in care,5 6 which is
reﬂected in the likelihood of patients being opted out
(appropriately or not) but also refusing treatment.5 7 8
There is some evidence that health prevention and pro-
motion activities in primary care are less frequent for
people with SMI despite frequent contact with the
system.9 As a result, premature mortality is much higher
in people with SMI compared with those without
SMI.10 11 A number of both system and individual
actions are necessary to address gaps in the treatment of
physical health in people with SMI.4
Several cross-sectional studies have indicated that indi-
viduals with SMI have increased rates of physical illness
compared with the general population;2 12–16 however,
these studies refer to data for limited periods of time,
focus on Scotland or London. We extend this work by
describing both SMI rates and patterns of comorbidity
in a matched UK population over a 12-year period.
A better understanding of comorbidity for people with
SMI is necessary for improving estimates to inform
policy and planning services.17 This paper examines
the:
1. Prevalence of SMI in the UK by country (England,
Northern Ireland (NI), Scotland and Wales), each
region in England and each deprivation quintile in
the UK, during the period 2000–2012.
2. Prevalence rates of 16 comorbidities in people with
SMI during (1) 2000–2012 and (2) 2011/2012 for
different types of SMI diagnoses (schizophrenia,
bipolar disorder, affective disorder and other types of
psychosis), compared with people without SMI and
by the most afﬂuent and most deprived quintile and
(3) the 5-year period 2007/2008–2011/2012 for the
combinations of comorbidities, for both people with
and without SMI.
METHODS
The Clinical Practice Research Datalink (CPRD) is a
large primary care database of anonymised longitudinal
medical records which contains detailed information on
diagnoses, referrals, prescribed treatments and test
results. The version we analysed has been described in
detail elsewhere.18 We used all available data from 627
practices to extract diagnoses information and aggre-
gated it in 12 yearly bins, from 1 April 2000 to 31 March
2012.
Generating a code list for SMI and other conditions
We used Read codes to identify the presence of SMI.
First, we identiﬁed relevant keywords (or key-stubs) and
codes, for example, ‘paranoi’ and E1*, covering the
mental health domain (see online appendix table A1).
Next, the CPRD was searched for codes that matched
the list in either the code or the description ﬁeld.
Finally, the matched code list was reviewed by clinical
experts, and a ﬁnal conservative list of codes was agreed.
SMI was deﬁned as: schizophrenia, affective disorder
(divided into bipolar or unspeciﬁed affective disorder)
or other types of psychoses, consistent with the inclusion
criteria for SMI registers in primary care general prac-
tice in the UK as part of the Quality and Outcomes
Framework (QOF) ﬁnancial incentive scheme. The
QOF was introduced in 2004 and links GP’s pay with
achievement of targets set across a range of chronic
conditions.19
The research team selected 16 conditions from an
extended list, based on previous work, incentivisation
under the QOF and a review of existing literature. The
QOF is relevant since quality of recording is excellent
for its domains and we included all except depression
(because of coding complexities and potential overlap
with SMI) and obesity. The conditions were: hyperten-
sion, diabetes (type I and II), asthma, hypothyroidism,
osteoarthritis, chronic kidney disease (CKD), learning
disability, coronary heart disease, epilepsy, chronic
obstructive pulmonary disease (COPD), cancer, stroke,
heart failure, rheumatoid arthritis, dementia and psoria-
sis. These were discussed and agreed a priori by all
authors, and codes associated with these conditions were
obtained through a similar approach to the one used for
patients with SMI and were mainly developed for previ-
ous work.20 All the code lists we used, as well as the SMI
categorisation, are available from http://www.
clinicalcodes.org,21 while more details on the Read code
selection process in this SMI context have been provided
elsewhere.22
Within each year, all patients registered with a CPRD
practice for the whole year and aged 18 or over were eli-
gible for inclusion. The ﬁnal SMI Read code list was
used to identify cases with schizophrenia, affective psych-
oses (bipolar disorder or other unspeciﬁed affective
psychosis) and other types of psychosis, in line with the
diagnoses used when compiling primary care QOF SMI
registers.23 If an individual received more than one SMI
diagnosis over the study period, we used the last avail-
able diagnosis to retrospectively ‘correct’ the original
diagnosis (ie, we assumed that the latest diagnosis was
the correct one). Within each year, each SMI case was
then matched on age, sex and general practice to ﬁve
randomly selected patients not associated with SMI up
until that time point.
Other sociodemographic characteristics
Deprivation was measured using the 2007 Index of
Multiple Deprivation (IMD) score in England,24 applied
to the practice postcode. Analogous deprivation indexes
were used for Welsh, Scottish and NI practices. One of
ﬁve deprivation quintiles, based on the deprivation
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distribution within each country, was assigned to each
individual in the sample.
Medications
We reported the number of individuals with one or
more prescriptions within a year for each of the follow-
ing medications: antipsychotic drugs (ﬁrst, second gen-
eration and depot injections), tricyclic antidepressants
(TCAs), selective serotonin reuptake inhibitors (SSRIs)
and other antidepressants.
Analysis
SMI prevalence rates were calculated overall, by depriv-
ation quintile and by practice region, across the study
period. We report patient characteristics for both SMI
and control cases, including prevalence rates for the
investigated comorbidities. Finally, we created detailed
comorbidity mapping tables for both groups, a common
practice when investigating disease clusters,12 25 to iden-
tify relevant patterns of comorbidity in SMI cases and
investigate how they differed to what is observed for con-
trols. Prevalence rates were calculated annually over the
study period (2000/2001–2011/2012), although we
focused on the last ﬁnancial year to investigate if the
comorbidity patterns differed by SMI diagnosis type
(schizophrenia, bipolar disorder, affective disorder and
other types of psychosis). We also calculated comorbidity
maps for combinations of comorbidities, for both SMI
and controls, aggregated over 5 years (2007/2008–2011/
2012).
RESULTS
The number of practices included in the sample
ranged from 434 practices in 2000/2001 to 569 in
2006/2007 (table 1; online appendix ﬁgure A1).
Numbers of individuals with SMI rose year on year
from 19 658 in 2000/2001 (434 practices) to a high of
33 117 in 2009/2010 (556 practices) and declined in
subsequent years (table 1).
In Scotland, in 2011/2012, the annual prevalence of
SMI was 0.73% compared with 0.69% in NI, 0.65% in
Wales and 0.63% in England (table 2 and ﬁgure 1). The
prevalence rate of SMI in Scotland did not increase
overall during the study period, though in the most
deprived quintile, some increases were observed. In con-
trast, rates increased in England, Wales and especially in
NI (from 0.48 in 2000/2001 to 0.69 in 2011/2012). With
the exception of the South West, the annual prevalence
rate of SMI increased across all English regions over the
study period (table 2). The greatest increases were
observed in the North East, North West and the East
Midlands. SMI prevalence was the highest in areas in the
two highest deprivation quintiles (table 2 and ﬁgure 1).
Changes over time were more evident in the most
deprived quintile in NI with rates more than doubling
over the 12-year period (0.49 in 2000/2001 to 1.16 in
2011/2012), with a great rise in 2007/2008 (table 2).
The mean number of years since the ﬁrst SMI diagnosis
increased from 11.7 (SD 11.5) in 2000/2001 to 13.2 (SD
11.8) in 2011/2012 and the mean years since the ﬁnal
diagnosis increased from 9.1 (SD 11.3) in 2000/2001 to
11.5 (SD 11.0) in 2011/2012 (table 3).
The prevalence rates for all of the diagnostic categor-
ies (bipolar disorder: 0.13–0.19; other SMI: 0.18–0.23;
and schizophrenia: 0.11–0.14) increased over the study
period with the least increase in unspeciﬁed/other
affective psychosis (0.06–0.07).
Medication: antipsychotic medication and antidepressants
The number of individuals with one or more prescription
for ﬁrst generation antipsychotic medications has steadily
declined over the 12 years (from 20.26% to 9.78%),
whereas second generation antipsychotic medications
have steadily increased (from 18.1% to 43%). Decreases
in depot injections were observed over time as shown in
table 3. An increase over the time period was observed
for SSRIs (from 18.1% to 25.75%), whereas a decrease
was observed for TCAs (from 14.03% to 9.21%).
Prevalence rates of comorbidities
Annual prevalence rates varied over the 12-year period
for those with and without SMI (table 1). There
appeared to be a greater increase in the mean number
of additional conditions in the SMI population over the
study period (0.6 in 2000/2001 to 1.0 in 2011/2012)
compared with control cases (0.5 in 2000/2001 to 0.6 in
2011/2012; table 1).
Over time, prevalence rates for comorbidities gener-
ally increased for both groups but the increases were
greater for the SMI group. For example, hypertension
prevalence increased from 12.2 to 18.3 between 2000/
2001 and 2011/2012 for the SMI group, but for the
control group, the increase was smaller from 14.2 to
16.3 over the same time period. There were some
notable exceptions: the rates for coronary heart disease
and heart failure fell for both groups, and the rates for
stroke remained relatively stable for the SMI group but
fell for the controls.
Although percentage of patients with two speciﬁc condi-
tions differed, comorbidity combinations were similar for
the patients with SMI and matched controls. The most
common comorbidity combination (percentage of
patients with 2 conditions) was diabetes and hypertension
and was experienced by 4.4% of patients with SMI (ﬁgure
2; online appendix tables A2 and A3). The percentages of
people with one of the conditions who also have other
conditions were higher for the SMI group for most condi-
tions (see online appendix table A4 and ﬁgure A2).
However, higher rates of hypertension were observed in
the controls with a diagnosis of diabetes, asthma, hypothy-
roidism, osteoarthritis, CKD, COPD and heart failure.
A variable pattern of comorbidity was observed across
the different SMI subgroups and areas of high and low
deprivation (see online appendix tables A5–7). When
we focused on 2011/2012 data and compared SMI and
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Table 1 Characteristics of the SMI population and the matched controls, over time
2000/2001 2001/2002 2002/2003 2003/2004 2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012
Counts (total)
Number of
practices
434 472 503 532 553 566 569 565 565 556 534 499
Number of
individuals
3 805 086 4 199 071 4 534 974 4 843 511 5 071 047 5 214 673 5 321 351 5 369 370 5 449 547 5 432 224 5 301 520 5 069 748
SMI 19 658 22 039 24 740 26 969 29 040 30 286 31 267 32 175 32 666 33 117 32 787 31 807
Controls 98 290 110 195 123 700 134 845 145 200 151 430 156 335 160 875 163 330 165 585 163 935 159 035
Counts (most affluent quintile)
Number of
practices
69 74 82 90 92 96 96 96 96 96 94 87
Number of
individuals
707 541 756 150 832 676 910 936 952 045 989 010 1 006 610 1 015 637 1 038 967 1 057 164 1 050 114 1 000 798
SMI 3103 3345 3769 4168 4506 4753 4795 4928 5002 5131 5193 4956
Controls 15 515 16 725 18 845 20 840 22 530 23 765 23 975 24 640 25 010 25 655 25 965 24 780
Percentage of
SMI most
affluent quintile
0.16 0.15 0.15 0.15 0.16 0.16 0.15 0.15 0.15 0.15 0.16 0.16
Counts (most deprived quintile)
Number of
practices
95 99 101 105 109 110 110 108 107 106 102 97
Number of
individuals
783 582 842 103 871 663 902 512 930 570 938 429 940 953 927 943 939 433 928 240 903 084 860 807
SMI 4668 5130 5639 6009 6363 6613 6795 6918 6945 7005 6964 6809
Controls 23 340 25 650 28 195 30 045 31 815 33 065 33 975 34 590 34 725 35 025 34 820 34 045
Percentage of
SMI most
deprived quintile
0.24 0.23 0.23 0.22 0.22 0.22 0.22 0.22 0.21 0.21 0.21 0.21
Percentage of male
SMI 45.42 46.18 47.10 47.75 48.02 48.42 48.49 48.89 48.63 48.86 48.82 48.93
Controls 45.42 46.18 47.10 47.75 48.02 48.42 48.49 48.89 48.63 48.86 48.82 48.93
Mean age (SD)
SMI 51.6 (17.6) 51.4 (17.5) 51.2 (17.5) 50.9 (17.4) 50.8 (17.2) 50.8 (17.1) 50.8 (17.0) 50.9 (16.9) 51.1 (16.8) 51.2 (16.8) 51.4 (16.8) 51.6 (16.7)
Control 51.6 (17.6) 51.4 (17.5) 51.2 (17.5) 50.9 (17.4) 50.8 (17.2) 50.8 (17.1) 50.8 (17.0) 50.9 (16.9) 51.1 (16.8) 51.2 (16.8) 51.4 (16.8) 51.6 (16.7)
Annual prevalence rates of comorbidities and mean number of conditions (in addition to SMI) in all patients diagnosed with SMI and matched controls
Hypertension
SMI 12.20 12.70 13.14 14.22 14.92 15.73 16.35 16.96 17.45 17.80 17.99 18.29
Controls 14.19 14.77 14.95 15.42 16.10 16.34 16.48 16.46 16.58 16.35 16.24 16.11
Continued
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Table 1 Continued
2000/2001 2001/2002 2002/2003 2003/2004 2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012
Diabetes (type I and II)
SMI 5.29 5.79 6.07 6.48 7.18 7.72 8.34 8.79 9.33 9.82 10.41 11.11
Controls 3.53 3.77 3.85 4.14 4.33 4.49 4.70 4.90 5.05 5.16 5.36 5.55
Asthma
SMI 5.80 6.14 6.48 7.06 7.29 7.54 7.67 7.82 8.20 8.29 8.18 7.88
Controls 5.44 5.48 5.74 5.75 5.93 5.98 5.88 6.01 5.98 6.03 5.85 5.47
Hypothyroidism
SMI 5.51 5.75 6.23 6.84 7.45 8.05 8.32 8.56 8.87 9.00 9.06 9.18
Controls 2.96 3.20 3.19 3.54 3.78 3.96 4.01 4.05 4.14 4.25 4.19 4.24
Osteoarthritis
SMI 8.98 9.05 9.21 9.44 9.60 9.80 9.80 10.05 10.41 10.38 10.71 10.79
Controls 9.36 9.42 9.20 9.24 9.28 9.51 9.53 9.44 9.58 9.61 9.63 9.50
Chronic kidney disease
SMI 0.28 0.32 0.45 0.55 0.67 0.96 5.48 7.02 7.53 7.88 8.01 8.24
Controls 0.26 0.29 0.30 0.36 0.44 0.57 3.19 3.89 4.14 4.27 4.25 4.16
Learning disability
SMI 1.33 1.31 1.28 1.24 1.29 1.37 1.48 1.46 1.46 1.75 1.89 1.86
Controls 0.13 0.16 0.15 0.15 0.15 0.16 0.18 0.18 0.16 0.22 0.21 0.22
Coronary heart disease
SMI 5.71 5.47 5.44 5.21 4.97 4.82 4.76 4.63 4.51 4.50 4.47 4.51
Controls 5.61 5.56 5.31 4.97 4.81 4.60 4.43 4.24 4.00 3.85 3.66 3.60
Epilepsy
SMI 2.03 2.19 2.17 2.40 2.54 2.60 2.56 2.61 2.55 2.59 2.66 2.58
Controls 0.70 0.76 0.75 0.72 0.82 0.75 0.77 0.75 0.76 0.70 0.71 0.70
COPD
SMI 1.89 2.01 2.05 1.94 2.10 2.26 2.49 2.74 2.94 3.12 3.20 3.46
Controls 1.36 1.40 1.47 1.43 1.56 1.60 1.60 1.66 1.72 1.72 1.81 1.80
Cancer
SMI 2.76 2.77 2.93 3.07 3.12 3.22 3.38 3.46 3.50 3.65 3.83 4.11
Controls 2.70 2.78 2.74 2.81 2.87 2.96 3.09 3.06 3.14 3.21 3.39 3.44
Stroke
SMI 3.64 3.69 3.63 3.53 3.47 3.52 3.45 3.55 3.52 3.59 3.75 3.75
Controls 2.51 2.48 2.42 2.24 2.21 2.09 2.15 2.08 2.09 1.98 1.97 2.07
Heart failure
SMI 2.28 2.05 2.07 1.99 1.86 1.74 1.55 1.44 1.34 1.31 1.37 1.41
Controls 1.64 1.55 1.44 1.30 1.15 1.06 0.97 0.90 0.88 0.79 0.77 0.79
Rheumatoid arthritis
SMI 0.92 0.89 0.84 0.86 0.91 0.88 0.89 0.92 0.90 0.95 0.99 1.04
Controls 0.91 0.97 0.94 0.99 0.95 0.95 0.97 0.98 0.92 0.91 0.97 0.95
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control cases within each SMI diagnosis subgroup, we
observed differences in prevalence rates for almost all
conditions in all groups (see online appendix table A5).
We noted large differences between the prevalence rates
of a number of conditions such as diabetes mellitus,
hypothyroidism, CKD for people with SMI and those
without SMI. There were also differences between SMI
diagnoses groups (schizophrenia, bipolar disorder,
affective disorder and other types of psychosis). For
example, the difference between prevalence rates of
people with schizophrenia and controls who also had a
diabetes diagnosis (13.42 compared with 6.01) was
larger than the difference between the other three SMI
diagnoses groups and controls. The difference between
prevalence rates of people with bipolar disorder and
controls who also had a hypothyroidism diagnosis (12.77
compared with 4.58) and a CKD diagnosis (10.41 com-
pared with 3.9) than the difference between the other
three SMI diagnoses groups and controls. In addition,
for diabetes mellitus, asthma, CHD, COPD, learning dis-
ability, osteoarthritis and epilepsy, we observed higher
prevalence rates in people with SMI in the most
deprived quintile (see online appendix table A6). For
hypothyroidism, CKD, psoriasis, cancer, stroke and
dementia, prevalence rates were higher in the most
afﬂuent quintile (see online appendix table A7).
DISCUSSION
Findings
This is the ﬁrst large longitudinal study to explore the
prevalence of SMI and comorbidity in the context of
deprivation. We identiﬁed a number of key ﬁndings: First,
we found that the prevalence of SMI, in the UK, increased
over the 12-year period from 2000 to 2012. The increase
was consistent across all diagnosis subgroups but highest in
bipolar disorder and other SMI. Increases were highest in
areas of high social deprivation. Second, the difference in
rates across England, NI, Wales and Scotland has narrowed
overtime. Third, the age at which people received their
diagnosis lowered over the 12 years (age stayed constant
while the mean number of years since the ﬁrst SMI diag-
nosis increased). Fourth, we observed an increase in the
average number of reported comorbidities for the SMI
group. Some conditions increased at a higher rate for
those with a SMI diagnosis: COPD, diabetes, hypothyroid-
ism and asthma. Whereas the rates for hypertension, CKD
and stroke increased in the SMI group in contrast to
control cases which showed a decrease. This also coincides
with yearly increase in the proportion of people with SMI
with one or more prescription of atypical antipsychotic
medications. Finally, a variable pattern of comorbidity was
observed across the different SMI subgroups and areas of
high and low deprivation.
Comparison with previous research
Our study is one of the latest in a growing number of
studies that have used electronic patient health records
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to examine epidemiological data and multimorbidity
associated with people with SMI.2 13 15 26 The prevalence
rate of SMI observed in the ﬁnal study year (2011/2012)
is lower than reported by the English QOF (0.63 com-
pared with 0.87),18 and previous estimates.27 Our 2007
rates for Scotland (0.71/0.72) were similar to those
recently reported (0.70).13 Differences are common in
studies which use different Read code lists to deﬁne SMI.
For example, the lower rates in our study may be partly
attributed to the exclusion of drug/alcohol-induced
psychoses, organic psychoses, dementia, unipolar depres-
sion, personality disorders and psychotic disorders in
childhood/adolescence. The publication of our Read
code lists, through http://www.clinicalcodes.org, will
facilitate future research in this ﬁeld and the comparison
of rates across future studies.
It is not possible within this study to explain the
reasons for the increase in SMI rates over time. Our
results indicate that people are getting diagnosed earlier.
However, further research is needed to explore the
factors that may contribute to these observed increases.
Although there have been recent studies providing
estimates of prevalence, they examined a more limited
set of comorbidities,2 16 they did not have UK coverage
or provide estimates for all SMI subgroups.13 15 To our
knowledge, there are currently no other comparable
studies that have examined rates of comorbidities over
such a long period of time. Some of our annual ﬁndings
are consistent with other studies. The 2011/2012 preva-
lence rates for eight conditions (hypertension, asthma,
hypothyroidism, CKD, epilepsy, cancer, stroke, psoriasis)
were higher than reported in two previous studies.13 15
Table 2 Annual severe mental illness (SMI) prevalence rates (all patients diagnosed with SMI) by geographical location and
area deprivation quintile, over time
2000/
01
2001/
02
2002/
03
2003/
04
2004/
05
2005/
06
2006/
07
2007/
08
2008/
09
2009/
10
2010/
11
2011/
12
UK
Overall 0.52 0.52 0.55 0.56 0.57 0.58 0.59 0.60 0.60 0.61 0.62 0.63
0 (most affluent) 0.44 0.44 0.45 0.46 0.47 0.48 0.48 0.49 0.48 0.49 0.49 0.50
1 0.46 0.47 0.50 0.51 0.53 0.54 0.54 0.55 0.56 0.56 0.57 0.58
2 0.51 0.52 0.53 0.53 0.54 0.54 0.55 0.56 0.57 0.58 0.58 0.58
3 0.55 0.56 0.58 0.61 0.63 0.64 0.65 0.66 0.66 0.68 0.69 0.70
4 (most deprived) 0.60 0.61 0.65 0.67 0.68 0.70 0.72 0.75 0.74 0.75 0.77 0.79
Country
England*
Overall 0.51 0.51 0.53 0.54 0.55 0.56 0.57 0.58 0.58 0.60 0.61 0.63
Most affluent 0.44 0.43 0.45 0.45 0.46 0.46 0.45 0.46 0.45 0.46 0.47 0.47
Most deprived 0.62 0.63 0.66 0.66 0.67 0.69 0.71 0.73 0.72 0.75 0.77 0.80
Northern Ireland†
Overall 0.48 0.48 0.50 0.53 0.55 0.56 0.58 0.62 0.64 0.64 0.67 0.69
Most affluent 0.41 0.44 0.44 0.48 0.48 0.51 0.53 0.54 0.56 0.56 0.59 0.60
Most deprived 0.49 0.49 0.52 0.58 0.66 0.71 0.74 1.03 1.04 1.09 1.09 1.16
Scotland‡
Overall 0.73 0.74 0.71 0.68 0.70 0.71 0.71 0.72 0.71 0.72 0.72 0.73
Most affluent 0.63 0.66 0.56 0.53 0.56 0.56 0.55 0.56 0.54 0.55 0.55 0.57
Most deprived 0.77 0.80 0.89 0.94 0.95 0.97 0.97 0.97 0.98 0.98 0.98 1.00
Wales§
Overall 0.48 0.50 0.54 0.59 0.61 0.62 0.63 0.64 0.64 0.65 0.65 0.65
Most affluent 0.49 0.5 0.53 0.56 0.59 0.61 0.61 0.62 0.6 0.6 0.63 0.59
Most deprived 0.43 0.48 0.53 0.56 0.58 0.59 0.61 0.61 0.61 0.64 0.65 0.66
English regions
North East 0.49 0.51 0.53 0.53 0.54 0.55 0.57 0.64 0.62 0.64 0.67 0.69
North West 0.54 0.56 0.60 0.62 0.65 0.67 0.67 0.68 0.68 0.69 0.72 0.74
Yorkshire 0.67 0.60 0.59 0.60 0.60 0.59 0.59 0.60 0.65 0.68 0.67 0.75
East-Midlands 0.45 0.46 0.49 0.51 0.54 0.54 0.56 0.53 0.53 0.57 0.57 0.65
West-Midlands 0.46 0.47 0.49 0.50 0.50 0.50 0.51 0.52 0.51 0.51 0.52 0.53
East of England 0.50 0.52 0.53 0.53 0.54 0.54 0.55 0.57 0.58 0.58 0.61 0.63
South West 0.55 0.54 0.54 0.53 0.52 0.51 0.51 0.49 0.50 0.52 0.52 0.52
South Central 0.45 0.45 0.47 0.48 0.49 0.50 0.50 0.52 0.51 0.51 0.51 0.51
London 0.58 0.60 0.64 0.65 0.66 0.68 0.69 0.71 0.71 0.73 0.73 0.73
South East 0.40 0.41 0.43 0.45 0.48 0.50 0.51 0.52 0.54 0.54 0.55 0.55
*Overall number of practices within each quintile from most affluent to most deprived: 73, 103, 103, 111 and 96.
†Overall number of practices within each quintile from most affluent to most deprived: 5, 5, 2, 7 and 3.
‡Overall number of practices within each quintile from most affluent to most deprived: 14, 11, 18, 11 and 14.
§Overall number of practices within each quintile from most affluent to most deprived: 7, 6, 11, 16 and 11.
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Other UK studies have not reported dementia preva-
lence rates for individuals with SMI; our 2011/2012
estimates were higher than the general population
(2.64 compared with 0.57). For the same time period,
Barnett et al12 reported 0.7 with dementia in the
general population comparing to 0.49 in our control
population for the same year (2007). When we com-
pared our prevalence rates for the controls with this
study for comparable conditions and year, most rates
were within a ±0.5% range. The rates in our study were
higher for diabetes (16.48 compared with 13.4), CKD
(3.19 compared with 1.9), psoriasis (3.02 compared
with 0.7) but lower for COPD (1.6 compared with 3.2).
Although there is a growing literature on analysis of
clustering conditions,25 it was not possible to compare
our ﬁndings on the most common comorbidity combi-
nations (percentage of patients with 2 conditions) with
any of the SMI studies. Although one other study exam-
ined combinations of comorbidities, percentages were
not reported.15
Others have also shown that the presence of a mental
health disorder (not just SMI) increased as the number
of physical morbidities and is much more likely in more
deprived people.12 It is possible that the increased
number of certain conditions may be linked with
increased prescriptions of antipsychotic medications.28–30
Furthermore, the lower annual prevalence levels in early
years in some conditions may be due to under-reporting
in primary care. It is possible that initiatives such as the
QOF, the Commissioning for Quality and Innovation
(CQUINs) payments framework and the
Cardiometabolic Health Resource31 may be helping to
improve diagnosis and thus leading to increases in preva-
lence rates. This may indicate a general underdiagnosis
of conditions and may therefore be an underestimation
of the prevalence among patients with SMI. Others have
noted that studies based on medical records will under-
estimate multimorbidity because some diseases are
undiagnosed, and because they will not identify people
who do not consult.32 In a separate paper, we show that
consultations increased over the 12-year period,33 which
ﬁts with previous evidence indicating that people who
consult more often may have more conditions diag-
nosed.34 Smith et al observed a systematic under-
recognition which might contribute to the substantial
cardiovascular-related morbidity and premature mortality
observed in patients with schizophrenia.12 Our data
would suggest that this may also be the case for other SMI
subgroups too.
The provision of good medical care tends to vary
inversely with need,35 and could account for the higher
rates of SMI and comorbidity in areas of higher social
deprivation; however, we speculate that better case ﬁnding,
driven by the QOF, partially accounts for the observed
increases in the comorbidity burden for the
QOF-incentivised SMI group, not observed in the
matched controls.20 36
Further research is required to examine the upward
trend in many of the conditions and action is urgently
required to identify the accurate prevalence rates for
people with SMI. The recent recommendation to
include mental health experts on all National Institute
for Health and Care Excellence (NICE) guideline
development groups for physical conditions to ensure
that the mental health aspects of conditions are com-
prehensively considered is timely.37 The ﬁndings are
relevant for NHS strategic and operational plans
addressing outcomes related to improving health, redu-
cing health inequalities and parity of esteem.38 There is
an ambition to achieve a genuine parity of esteem
between mental and physical health by 2020, and an
expectation that each clinical commissioning group is
spending on mental health services in 2015/2016
increases in real terms.39 The patterns of comorbidities
in the most afﬂuent and most deprived quintiles indi-
cate that the effect of deprivation is worth further
exploration in conjunction with the impact on clinical
activity. For example, our data may suggest that people
with SMI registered at a more afﬂuent practice may be
more likely to undergo regular monitoring making the
diagnosis of unrelated diseases such as cancer and
hypothyroidism more likely. It may also be worth inves-
tigating comorbidity interactions as the diagnosis of
Figure 1 Prevalence of severe mental illness by UK country
(top) and deprivation quintile (bottom), over time.
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Table 3 Prevalence, number and gender for all individuals with severe mental illness (SMI) diagnosis*, mean years with first and latest SMI diagnosis and prescribed
medications†, over time
2000/2001 2001/2002 2002/2003 2003/2004 2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012
Prevalence of individuals with SMI diagnosis
Schizophrenia 0.11 0.11 0.12 0.12 0.13 0.13 0.13 0.14 0.13 0.14 0.14 0.14
Bipolar disorder 0.13 0.13 0.14 0.15 0.15 0.16 0.16 0.17 0.17 0.18 0.18 0.19
Unspecified/other
affective psychosis
0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.07 0.07
Other types of
psychosis
0.18 0.18 0.19 0.2 0.2 0.2 0.2 0.21 0.21 0.21 0.22 0.23
Number of individuals with SMI diagnosis (not exclusively)
Schizophrenia 4098 4674 5268 5842 6339 6727 7059 7281 7296 7323 7205 7029
Bipolar disorder 4906 5613 6352 7083 7784 8259 8701 9055 9332 9715 9727 9496
Unspecified/other
affective psychosis
1938 2150 2392 2573 2839 2999 3255 3398 3551 3690 3696 3605
Other SMI 6862 7691 8764 9551 10 226 10 628 10 857 11 226 11 484 11 623 11 665 11 631
Percentage of male individuals with SMI diagnoses
Schizophrenia 54.86 55.63 57.52 58.37 58.98 59.86 60.41 60.86 60.68 61.35 61.5 61.79
Bipolar disorder 39.52 39.66 39.97 39.93 39.92 39.77 39.46 39.72 39.71 39.66 39.8 39.49
Unspecified/other
affective psychosis
32.04 33.26 34.36 35.29 35.51 35.45 36.65 37.7 37.37 37.32 37.28 37.14
Other types of
psychosis
48.32 49.25 49.55 50.38 50.76 51.4 51.39 51.88 51.68 52.34 52.2 52.51
Mean number of years with SMI diagnosis (SD)
First SMI diagnosis 11.7 (11.5) 11.8 (11.6) 11.8 (11.6) 11.8 (11.6) 11.8 (11.6) 12.1 (11.7) 12.2 (11.7) 12.3 (11.6) 12.6 (11.7) 12.8 (11.7) 13.0 (11.7) 13.2 (11.8)
Latest SMI
diagnosis
9.1 (11.3) 9.2 (11.3) 9.4 (11.2) 9.5 (11.2) 9.6 (11.1) 9.9 (11.1) 10.1 (11.0) 10.3 (10.9) 10.6 (10.9) 10.9 (10.9) 11.3 (11.0) 11.5 (11.0)
Antipsychotics‡
First generation
(conventional)
20.26 20.11 17.64 15.31 14.79 13.84 12.71 11.94 11.03 10.12 9.39 8.78
Second generation
(atypical)
18.1 23.03 27.12 30.68 33.33 35.77 37.75 38.8 39.82 40.57 41.77 43.02
Depot 5.95 5.65 5.15 4.69 4.45 4.13 3.83 3.65 3.5 3.5 3.32 3.23
Antidepressants‡
Tricyclic 14.03 12.94 12.23 11.81 11.17 10.32 9.81 9.4 9.28 9.19 9.32 9.21
Selective serotonin
reuptake inhibitors
18.13 19.65 20.27 20.41 20.92 21.16 22.58 22.95 23.8 24.38 25.23 25.75
Other
antidepressants§
6.87 8.7 10.05 11.18 12.21 12.3 12.67 13.17 13.31 13.83 14.5 14.96
*In instances where an individual received more than one SMI diagnostic subcategory diagnoses during the study period, the patient was assigned to the last diagnostic category received, since
it was likely to be based on a greater knowledge of the individual’s clinical history.
†Patients were considered to be associated with a medication group if they received at least one prescription of a relevant drug within the respective year.
‡Organised by chapters in British National Formulary (BNF) 67 (March 2014).
§Not listed in BNF 67 (March 2014).
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Figure 2 (top) Patterns of comorbidities for SMI (top) and control patients (bottom) over 5 years (2007/2008–2011/2012);
percentage of patients with two specific conditions (see also table A3). CHD, coronary heart disease; CKD, chronic kidney
disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; LD, learning disability; RA, rheumatoid arthritis; SMI,
severe mental illness.
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certain conditions may be made easier by the presence
of an SMI diagnosis.40
The interaction between mental and physical health
problems increases the costs of care which have been
shown to be greater than the combined costs of having
the individual conditions alone.41 Despite this, the level
of mental health funding is not commensurate with
burden and is lower than other chronic conditions.42
Having up to date epidemiological data helps to pin-
point how healthcare providers need to meet the chal-
lenge of providing good quality treatment and care to
people with SMI.
Strengths and limitations
To our knowledge, this is the ﬁrst 12-year longitudinal
study to examine prevalence rates of 16 comorbidities
for people with SMI compared with a matched control
group without SMI. We presented these by deprivation
quintile and by type of SMI diagnosis. This study demon-
strates how research can use routinely collected health-
care data for this purpose.43
Databases which use routinely collected clinical data,
such as the CPRD, come with certain limitations.
Although the CPRD is representative of the UK in its dis-
tribution of practice location deprivation, it tends to
recruit larger than average practices,18 while the version
we analysed only included practices utilising one of
three major clinical computer systems available
(VISION). Although differences in performance across
systems have been observed,44 such issues may be less
relevant in this setting where we focus on prevalence
rates. The main limitation, however, is that this is an
observational study and the possibility of unmeasured
confounding is present. Controls were matched for age,
gender and practice (and since deprivation was mea-
sured at the practice level, on deprivation as well).
Other important parameters such as obesity, unemploy-
ment, ethnicity, smoking status, alcohol or illegal drug
use were not extracted as they may be recorded inaccur-
ately or missing. However, the nature of the study was
purely descriptive and we do not attempt to quantify
associations, rather quantify overall differences in phys-
ical comorbidity irrespective of the potential underlying
factors (a much stricter matching would be at risk of
overcontrolling). Since we did not have speciﬁc hypoth-
eses about the variations in prevalence rates across
deprivation quintiles or between SMI and control cases,
and the potential comparisons are numerous, we
refrained from testing for statistically signiﬁcant differ-
ences. Instead we focussed on the size of the prevalence
rates and their apparent differences. Furthermore, statis-
tical signiﬁcance is less meaningful for data sets of this
size.45 Second, the deprivation scores relate to the area
location of the general practice and not of the indivi-
dual’s area of residence and therefore may be a less
accurate proxy of the individual level of deprivation.46
Third, we could not quantify the severity of mental
illness or of the comorbidities we investigated. Fourth,
some of our estimates for speciﬁc countries and depriv-
ation quintiles, especially for NI, are based only on a
very small number of practices. Fifth, accurate identiﬁca-
tion of people with SMI requires a valid and reliable
measurement of diagnosis. However, not only is there is
a lack of agreement on precise diagnostic category after
a diagnostic assessment,47 psychiatric diagnoses are
highly variable and changeable over time and people
will move between diagnoses as the nature of their
illness becomes clearer (or indeed less clear). Finally,
studies based on medical records will underestimate
multimorbidity because some diseases are undiagnosed,
and because they will not identify people who do not
consult.32
Conclusions and implications for research and practice
Our ﬁndings help our understanding of the prevalence
of SMI and physical comorbidities and show rising
inequalities in the pattern and number of different
comorbidities and will be of interest to the scientiﬁc com-
munity, policymakers, people with SMI, their carers and
professionals. Reducing these health inequalities will
require adequately funded vigorous health prevention
and promotion to improve the management of
comorbidities with more intense action in areas of
greater social and economic disadvantage. Exactly how
and where this is done requires urgent attention and
should be informed by the patterns of comorbidity that
are most common for this group. This research provides
further evidence for a number of recommendations for
the NHS that have recently been made including:
▸ Commissioners and service providers need to be
clear about the responsibilities of primary and sec-
ondary care services for monitoring and managing
the physical health of people with mental health pro-
blems, starting from the beginning of treatment with
identiﬁed health needs acted on quickly.
▸ All mental health professionals should receive basic
physical health training as part of their mandatory
training.
▸ Rates of people accessing interventions included in
the QOF should be in line with predicted prevalence
of the illness.48 49
The knowledge added in this study about patterns of
comorbidities associated with SMI will be helpful in the
development of studies aimed at investigating causal
associations. Multimorbidity is a possible confounding
factor, so will be important for planning intervention
trials ensuring that participants with SMI are representa-
tive regarding their morbidity burden and patterns of
illnesses.
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